重组FVIII与艾美赛珠单抗对血友病A内皮细胞功能非止血效应的研究
本研究评估了多种重组FVIII产品及艾美赛珠单抗对血友病A患者来源的内皮细胞功能的影响。所有rFVIII产品均显著改善HA-BOECs的增殖、迁移、成管和通透性,但Elocta活性较低且与BOECs结合减少。在严重HA小鼠模型中,Nuwiq和Altuviiio恢复血管通透性,Nuwiq效果最强,而Elocta部分纠正。艾美赛珠单抗在体外和体内均无可测量效应。
要点
- rFVIII产品可改善HA患者内皮细胞功能,但存在产品间差异。
- Elocta对内皮细胞活性及结合均低于Nuwiq。
- 艾美赛珠单抗对HA内皮细胞功能无显著影响。
核心结论
- FVIII在HA内皮细胞生物学和血管稳态中具有重要作用,不同rFVIII产品对内皮细胞功能的影响存在差异。
研究设计与样本
- 使用血友病A患者来源的血液外生长内皮细胞(BOECs)进行体外功能实验,并在严重HA小鼠模型中进行体内验证。
主要发现
- 所有rFVIII产品均显著改善HA-BOECs的增殖、迁移、成管和通透性,但Elocta除外,其活性持续降低且与BOECs结合减少。
- 在严重HA小鼠模型中,Nuwiq和Altuviiio均恢复血管通透性,Nuwiq效果最强,Elocta仅部分纠正;Nuwiq促体内血管生成作用大于Elocta,Altuviiio居中。
- 艾美赛珠单抗在体外和体内均未显示可测量的效应。
临床怎么用
- 不同rFVIII产品对内皮细胞功能的影响存在差异,可能影响血友病A治疗的长期血管健康结局。
局限性
- 研究仅使用体外患者来源内皮细胞和小鼠模型,尚未在人体中验证这些非止血效应的临床意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hemophilia A (HA) is a rare x-linked bleeding disorder caused by the absence or dysfunction of coagulation factor VIII (FVIII). Beyond its role in coagulation, FVIII contributes to endothelial cell biology, but the relevance of these extra-coagulative effects remains unclear. Treatments include prophylaxis with FVIII concentrates or non-factor therapies such as emicizumab (Hemlibra). Recombinant FVIII (rFVIII) products differ in molecular design, including the host cell line used for production and modifications introduced to extend half-life, which may influence their biological activity. We assessed the impact of rFVIII products with molecular modifications to extend half-life (Elocta [Fc-fusion], Adynovate and Jivi [PEGylated], Altuviiio [Fc-fusion, vWF D'D3 domain, and XTEN polypeptides]) and those without modifications (Nuwiq, Advate), as well as emicizumab (a bispecific antibody), on blood outgrowth endothelial cells (BOECs) derived from HA patients, whose cellular functions were previously shown to be defective. All rFVIII products significantly improved HA-BOECs proliferation, migration, tubulogenesis, and permeability except Elocta, which consistently exhibited reduced activity and reduced binding to BOECs compared with Nuwiq. In a mouse model of severe HA, both Nuwiq and Altuviiio restored vascular permeability, with Nuwiq showing the strongest effect whereas Elocta provided partial correction. Similarly, Nuwiq promoted greater in vivo angiogenesis than Elocta, while Altuviiio had an intermediate effect. Emicizumab had no measurable effect either in vitro or in vivo. These data underscore the emerging importance of FVIII in HA ECs biology and vascular homeostasis, with potential long-term clinical implications for biomarker development and the optimization of HA treatment beyond conventional bleeding control.
引用
- Olgasi C, Venturin G, Borsotti C, et al. Non-hemostatic effects of recombinant FVIII and emicizumab on endothelial cell function in hemophilia A. Blood Adv. 2026. PMID: 42962224. doi:10.1182/bloodadvances.2026019646
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。